Rapid Micro Biosystems (NASDAQ: RPID – Get Rating) is one of 43 publicly traded companies in the “analytical instruments” sector, but how does it stack up against its peers? We will compare Rapid Micro Biosystems to related companies based on strength of institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.
Insider and Institutional Ownership
69.8% of Rapid Micro Biosystems shares are held by institutional investors. By comparison, 62.8% of the shares of all Analytical Instruments companies are held by institutional investors. 38.0% of the shares of Rapid Micro Biosystems are held by insiders. By comparison, 13.5% of the shares of all Analytical Instruments companies are held by insiders. Strong institutional ownership is an indication that endowments, large fund managers, and hedge funds believe a company will outperform the market over the long term.
This table compares the net margins, return on equity and return on assets of Rapid Micro Biosystems and its peers.
|Net margins||Return on equity||return on assets|
|Rapid Micro Biosystems Competitors||-250.85%||6.38%||-11.11%|
This is a breakdown of recent ratings from Rapid Micro Biosystems and its peers, as reported by MarketBeat.com.
|Sales Ratings||Hold odds||Buy reviews||Strong buy odds||Rating|
|Rapid Micro Biosystems Competitors||329||1347||1834||59||2.45|
Rapid Micro Biosystems currently has a consensus target price of $22.67, suggesting a potential upside of 413.98%. As a group, the “Analytical Instruments” companies have an upside potential of 29.54%. Given Rapid Micro Biosystems’ stronger consensus rating and higher likely upside, analysts clearly believe that Rapid Micro Biosystems is more favorable than its peers.
Benefits and evaluation
This table compares the revenue, earnings per share, and valuation of Rapid Micro Biosystems and its peers.
|Gross revenue||Net revenue||Price/earnings ratio|
|Rapid microbiosystems||$23.23 million||-73.52 million dollars||-0.21|
|Rapid Micro Biosystems Competitors||$1.16 billion||$344.59 million||-27.17|
Rapid Micro Biosystems peers have higher revenue and profit than Rapid Micro Biosystems. Rapid Micro Biosystems trades at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
About Rapid Micro Biosystems (Get an evaluation)
Rapid Micro Biosystems, Inc., a life science technology company, provides products for the detection of microbial contamination in the manufacturing of pharmaceutical, medical and personal care products in North America, Europe and Asia. The company offers the Growth Direct platform, which includes the Growth Direct system, proprietary consumables, laboratory information management system connection software, and comprehensive customer support and validation services. Its platform automates and modernizes manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides installation and verification services, technical training and support. Its solutions are used in environmental monitoring, water analysis, bioburden and sterility release applications. The company was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. Rapid Micro Biosystems, Inc. was incorporated in 2006 and is headquartered in Lowell, Massachusetts.
Get news and reviews for Rapid Micro Biosystems Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Rapid Micro Biosystems and related companies with MarketBeat.com’s free daily email newsletter.